Agency Forms Undergoing Paperwork Reduction Act Review, 1499-1500 [2025-00159]
Download as PDF
<![CDATA[
Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices
D In January 2024, CDC affirmed
existing viral-first testing
recommendations among people with
recent HCV exposure (https://
www.cdc.gov/hepatitis-c/hcp/diagnosistesting/#:∼:text=HCV%20RNA%20
testing%20for,a%20
syringe%20service%20program);
D In January 2024, CDC began the
process of updating HCV testing
guidance for clinicians and
laboratorians, including evaluating
testing strategies for the general
population that include tests for viral
markers in the first testing step (e.g.,
‘‘viral-first’’); and
D In June 2024, the FDA authorized
an HCV RNA CLIA-waived near pointof-care test for the diagnosis of current
HCV infection.
lotter on DSK11XQN23PROD with NOTICES1
Public Participation and Public
Comment
Public engagement will entail listenonly observation of information shared
on day 1 and day 2. If members of the
public have input on the questions
asked during the meeting, those public
comments can be collected through
regulations.gov using Docket CDC–
2025–0002 on or before February 19,
2025, and will be included in the final
meeting report. Written comments must
be submitted on or before February 19,
2025.
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign. Do not submit
comments by email. CDC does not
accept comment by email.
Noah Aleshire,
Chief Regulatory Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2025–00204 Filed 1–7–25; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
17:50 Jan 07, 2025
Jkt 265001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–25–24FS]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Needle
Exchange Utilization Survey (NEXUS)’’
to the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on May 28, 2024, to obtain
comments from the public and affected
agencies. CDC received one comment
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
1499
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Needle Exchange Utilization Survey
(NEXUS)—New—National Center for
HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The opioid crisis in the U.S. has led
to steep increases in overdose, Hepatitis
C Virus (HCV) incidence, and HIV
clusters and outbreaks among people
who inject drugs (PWID). These
alarming trends indicate an urgent need
to strengthen interventions to prevent
morbidity and mortality and
transmission of infectious disease
among PWID. Syringe services programs
(SSPs) are evidence-based, highly
effective prevention programs that have
expanded in many areas in the United
States to respond to the increasing
needs of providing HIV and HCV
prevention and other health and social
services to PWID and their
communities. Due to an increase in HCV
and HIV related to injection drug use
(IDU), it is now critical to understand
current patterns of IDU for the
prevention of these infectious diseases
and other injection related harms. Data
to inform these prevention efforts are
needed nationally, particularly from
non-urban settings that have
experienced increases in IDU and where
current surveillance activities are nonexistent or limited.
The purpose of the Needle Exchange
Utilization Survey (NEXUS) is to
develop a surveillance system to
monitor drug use, prevention behaviors,
and the infectious disease consequences
of drug use in 6–15 select urban and
non-urban areas of the U.S. that the
opioid crisis has impacted. Such a
surveillance system is needed to inform
prevention efforts and policy. The
specific objectives of the project are to
assess the following among persons who
inject drugs who are recruited in SSPs
and their peers who use drugs through
peer-driven recruitment: (1) drug use
and sexual behaviors, injection risk
networks, receipt of prevention services,
and barriers to prevention and care; and
(2) the prevalence of HIV and HCV
infections.
E:\FR\FM\08JAN1.SGM
08JAN1
1500
Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices
CDC requests OMB approval for an
estimated 3,126 total annualized burden
hours. Participation is voluntary and
there are no costs to the respondents
other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Form
Persons Screened ..........................................
Persons Screened ..........................................
Persons who give permission .........................
Persons who give permission .........................
Eligible Participants .........................................
Eligible Participants .........................................
Eligibility Screening Form English .................
Eligibility Screening Form Spanish ................
Model Project Consent Form English ............
Model Project Permission Form Spanish ......
NEXUS Survey English ..................................
NEXUS Survey Spanish ................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2025–00159 Filed 1–7–25; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–25–1360]
Agency Forms Undergoing Paperwork
Reduction Act Review
lotter on DSK11XQN23PROD with NOTICES1
Number of
respondents
Respondent
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘CryptoNet
Case Report Form’’ to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on October
21, 2024 to obtain comments from the
public and affected agencies. CDC did
not receive comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
VerDate Sep<11>2014
17:50 Jan 07, 2025
Jkt 265001
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street, NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
CryptoNet Case Report Form (OMB
Control No. 0920–1360, Exp. 1/31/
2025)—Revision—National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The Waterborne Disease Prevention
Branch (WDPB) in the Division of
Foodborne, Waterborne, and
Environmental Diseases (DFWED) works
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
5,400
600
4,050
450
4,050
450
Number of
responses per
respondent
1
1
1
1
1
1
Average
burden per
response
(hours)
5/60
5/60
5/60
5/60
30/60
30/60
to prevent domestic and global waterrelated diseases. The WDPB is
comprised of five teams, including the
Domestic Waterborne Disease
Epidemiology and Response (WDER)
Team, which focuses on the prevention
and control of waterborne-related
diseases and outbreaks in the United
States. One of the diseases included in
the team’s work is cryptosporidiosis, an
acute diarrheal disease caused by
infection with Cryptosporidium
parasites.
The Case Surveillance Program is a
subunit within the Domestic WDER
Team that focus on the data collection
and management activities of five
waterborne diseases, including
cryptosporidiosis, in the United States.
The Case Surveillance Program’s current
scope of work includes modernizing
data collection and management,
enabling data connections, and
improving public data access to aid
public health action.
CryptoNet is the first molecular
tracking system for Cryptosporidium in
the United States. To meet the needs of
the CryptoNet and Case Surveillance
Program, and the needs of local officials,
the CryptoNet case report form (CRF)
was developed. The CRF includes a set
of data elements that can be used to
identify exposures trends in outbreakand non-outbreak-associated
Cryptosporidium cases, to generate
hypotheses about the sources of
infection in clusters or outbreaks, and to
identify strategies to prevent and control
Cryptosporidium cases, clusters, or
outbreaks.
Data from the CRF will be used by
federal, state, and local public health
officials responsible for conducting
interviews with reported cases of
cryptosporidiosis in their jurisdiction in
order to systemically assess core
exposure elements and risk factors
among cases of cryptosporidiosis.
Collected data will be used by CDC staff
to inform cryptosporidiosis sporadic
E:\FR\FM\08JAN1.SGM
08JAN1
]]>Agencies
[Federal Register Volume 90, Number 5 (Wednesday, January 8, 2025)]
[Notices]
[Pages 1499-1500]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00159]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-25-24FS]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Needle Exchange Utilization Survey
(NEXUS)'' to the Office of Management and Budget (OMB) for review and
approval. CDC previously published a ``Proposed Data Collection
Submitted for Public Comment and Recommendations'' notice on May 28,
2024, to obtain comments from the public and affected agencies. CDC
received one comment related to the previous notice. This notice serves
to allow an additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Needle Exchange Utilization Survey (NEXUS)--New--National Center
for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The opioid crisis in the U.S. has led to steep increases in
overdose, Hepatitis C Virus (HCV) incidence, and HIV clusters and
outbreaks among people who inject drugs (PWID). These alarming trends
indicate an urgent need to strengthen interventions to prevent
morbidity and mortality and transmission of infectious disease among
PWID. Syringe services programs (SSPs) are evidence-based, highly
effective prevention programs that have expanded in many areas in the
United States to respond to the increasing needs of providing HIV and
HCV prevention and other health and social services to PWID and their
communities. Due to an increase in HCV and HIV related to injection
drug use (IDU), it is now critical to understand current patterns of
IDU for the prevention of these infectious diseases and other injection
related harms. Data to inform these prevention efforts are needed
nationally, particularly from non-urban settings that have experienced
increases in IDU and where current surveillance activities are non-
existent or limited.
The purpose of the Needle Exchange Utilization Survey (NEXUS) is to
develop a surveillance system to monitor drug use, prevention
behaviors, and the infectious disease consequences of drug use in 6-15
select urban and non-urban areas of the U.S. that the opioid crisis has
impacted. Such a surveillance system is needed to inform prevention
efforts and policy. The specific objectives of the project are to
assess the following among persons who inject drugs who are recruited
in SSPs and their peers who use drugs through peer-driven recruitment:
(1) drug use and sexual behaviors, injection risk networks, receipt of
prevention services, and barriers to prevention and care; and (2) the
prevalence of HIV and HCV infections.
[[Page 1500]]
CDC requests OMB approval for an estimated 3,126 total annualized
burden hours. Participation is voluntary and there are no costs to the
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Respondent Form Number of responses per per response
respondents respondent (hours)
----------------------------------------------------------------------------------------------------------------
Persons Screened...................... Eligibility Screening 5,400 1 5/60
Form English.
Persons Screened...................... Eligibility Screening 600 1 5/60
Form Spanish.
Persons who give permission........... Model Project Consent 4,050 1 5/60
Form English.
Persons who give permission........... Model Project Permission 450 1 5/60
Form Spanish.
Eligible Participants................. NEXUS Survey English.... 4,050 1 30/60
Eligible Participants................. NEXUS Survey Spanish.... 450 1 30/60
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2025-00159 Filed 1-7-25; 8:45 am]
BILLING CODE 4163-18-P
